Cargando…
Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients
Pleiotrophin is a heparin-binding growth factor involved in the differentiation and proliferation of neuronal tissue during embryogenesis, and also secreted by melanoma and breast carcinoma cells. Pleiotrophin exhibits mitogenic and angiogenic properties and has been shown to influence the vascular...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364151/ https://www.ncbi.nlm.nih.gov/pubmed/11953815 http://dx.doi.org/10.1038/sj.bjc.6600202 |
_version_ | 1782153882079592448 |
---|---|
author | Jäger, R List, B Knabbe, C Souttou, B Raulais, D Zeiler, T Wellstein, A Aigner, A Neubauer, A Zugmaier, G |
author_facet | Jäger, R List, B Knabbe, C Souttou, B Raulais, D Zeiler, T Wellstein, A Aigner, A Neubauer, A Zugmaier, G |
author_sort | Jäger, R |
collection | PubMed |
description | Pleiotrophin is a heparin-binding growth factor involved in the differentiation and proliferation of neuronal tissue during embryogenesis, and also secreted by melanoma and breast carcinoma cells. Pleiotrophin exhibits mitogenic and angiogenic properties and has been shown to influence the vascular supply, expansion and metastasis of tumour cells. Our aim was to study the serum and plasma concentrations of pleiotrophin and the classical angiogenic growth factor vascular endothelial growth factor. Using a specific ELISA-test we studied patients with small cell lung cancer (n=63), and patients with non-small cell lung cancer (n=22) in comparison to healthy control subjects (n=41). In most of the lung cancer patients (81%), we found serum levels of pleiotrophin above those of control subjects (P<0.001). Of the 63 small cell lung cancer patients in the study pleiotrophin serum levels were elevated in 55 cases (87%) and in 14 cases (63%) of the 22 non-small cell lung cancer patients. Pleiotrophin mean serum concentrations were 10.8-fold higher in the tumour patient group as compared to the control group (P<0.001). Furthermore, pleiotrophin serum levels correlated positively with the stage of disease and inversely with the response to therapy. Plasma vascular endothelial growth factor concentrations were elevated in only in 28.6% of small cell lung cancer and 45.5% of non-small cell lung cancer patients by an average of 2.3-fold. Quite strikingly, there was no apparent correlation between the plasma vascular endothelial growth factor concentration and the stage of disease. Our study suggests that pleiotrophin may be an early indicator of lung cancer and might be of use in monitoring the efficacy of therapy, which needs to be confirmed by larger studies. British Journal of Cancer (2002) 86, 858–863. DOI: 10.1038/sj/bjc/6600202 www.bjcancer.com © 2002 Cancer Research UK |
format | Text |
id | pubmed-2364151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23641512009-09-10 Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients Jäger, R List, B Knabbe, C Souttou, B Raulais, D Zeiler, T Wellstein, A Aigner, A Neubauer, A Zugmaier, G Br J Cancer Clinical Pleiotrophin is a heparin-binding growth factor involved in the differentiation and proliferation of neuronal tissue during embryogenesis, and also secreted by melanoma and breast carcinoma cells. Pleiotrophin exhibits mitogenic and angiogenic properties and has been shown to influence the vascular supply, expansion and metastasis of tumour cells. Our aim was to study the serum and plasma concentrations of pleiotrophin and the classical angiogenic growth factor vascular endothelial growth factor. Using a specific ELISA-test we studied patients with small cell lung cancer (n=63), and patients with non-small cell lung cancer (n=22) in comparison to healthy control subjects (n=41). In most of the lung cancer patients (81%), we found serum levels of pleiotrophin above those of control subjects (P<0.001). Of the 63 small cell lung cancer patients in the study pleiotrophin serum levels were elevated in 55 cases (87%) and in 14 cases (63%) of the 22 non-small cell lung cancer patients. Pleiotrophin mean serum concentrations were 10.8-fold higher in the tumour patient group as compared to the control group (P<0.001). Furthermore, pleiotrophin serum levels correlated positively with the stage of disease and inversely with the response to therapy. Plasma vascular endothelial growth factor concentrations were elevated in only in 28.6% of small cell lung cancer and 45.5% of non-small cell lung cancer patients by an average of 2.3-fold. Quite strikingly, there was no apparent correlation between the plasma vascular endothelial growth factor concentration and the stage of disease. Our study suggests that pleiotrophin may be an early indicator of lung cancer and might be of use in monitoring the efficacy of therapy, which needs to be confirmed by larger studies. British Journal of Cancer (2002) 86, 858–863. DOI: 10.1038/sj/bjc/6600202 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-03-18 /pmc/articles/PMC2364151/ /pubmed/11953815 http://dx.doi.org/10.1038/sj.bjc.6600202 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Jäger, R List, B Knabbe, C Souttou, B Raulais, D Zeiler, T Wellstein, A Aigner, A Neubauer, A Zugmaier, G Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients |
title | Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients |
title_full | Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients |
title_fullStr | Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients |
title_full_unstemmed | Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients |
title_short | Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients |
title_sort | serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients |
topic | Clinical |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364151/ https://www.ncbi.nlm.nih.gov/pubmed/11953815 http://dx.doi.org/10.1038/sj.bjc.6600202 |
work_keys_str_mv | AT jagerr serumlevelsoftheangiogenicfactorpleiotrophininrelationtodiseasestageinlungcancerpatients AT listb serumlevelsoftheangiogenicfactorpleiotrophininrelationtodiseasestageinlungcancerpatients AT knabbec serumlevelsoftheangiogenicfactorpleiotrophininrelationtodiseasestageinlungcancerpatients AT souttoub serumlevelsoftheangiogenicfactorpleiotrophininrelationtodiseasestageinlungcancerpatients AT raulaisd serumlevelsoftheangiogenicfactorpleiotrophininrelationtodiseasestageinlungcancerpatients AT zeilert serumlevelsoftheangiogenicfactorpleiotrophininrelationtodiseasestageinlungcancerpatients AT wellsteina serumlevelsoftheangiogenicfactorpleiotrophininrelationtodiseasestageinlungcancerpatients AT aignera serumlevelsoftheangiogenicfactorpleiotrophininrelationtodiseasestageinlungcancerpatients AT neubauera serumlevelsoftheangiogenicfactorpleiotrophininrelationtodiseasestageinlungcancerpatients AT zugmaierg serumlevelsoftheangiogenicfactorpleiotrophininrelationtodiseasestageinlungcancerpatients |